BackgroundHuman epidermal growth factor receptor 2(HER-2) is the most prominent therapeutic target for gastric (G)/gastroesophageal junction (GEJ) cancer. Guidelines recommend its use for treating G/GEJ cancers. However. targeted therapy did not significantly improve survival outcomes compared to those with neoadjuvant therapy. https://www.marcelovicente.com/product-category/my-gyeol-fit-tint-brow/